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ABSTRACT 
 
   The increasing development of drugs such as antidep ressants and hormones led to serious  
environmental and health p roblems, becoming mandatory  to study  different ways to remove a 
selective serotonin re-up take inhibitor like fluoxetine (FLX) and estrogens like 17α- 
ethiny lestradiol (EE2) during the wastewater treatment p rocess . The study  was carried out by  
using activated sludge samp les from the Faro Northwest wastewater treatment p lant (WWT P) to 
isolate bacteria under aerobic conditions in order to test their resistance in the p resence of FLX 
and EE2 and investigate the biodegradability  of chosen pharmaceuticals. In the p resent study, the 
identification of bacterial isolates was performed by  sequencing the 16S rRNA gene of the 
obtained resistant bacteria. The obtained isolates which showed the ability  to grow in the 
p resence of 20 and 50 mg/L FLX were Pseudomonas putida, Enterobacter ludwigii, 
Pseudomonas nitritireducens, Alcaligenes faecalis, Pseudomonas aeruginosa, Pseudomonas 
nitroreducens and in the p resence of 15 mg/L EE2 were Acinetobacter bouvetii, Acinetobacter 
kookii, Pantoea agglomerans Shinella zoogloeoides. These isolates were identified as FLX and 
EE2 degraders for the first time. FLX and EE2 biodegradation assays was performed in liquid 
medium. The results showed that for 20 mg/L FLX the bacterial isolate Pseudomonas 
nitroreducens disp layed the highest removal efficiency  of 55 ± 1% and for 15 mg/L EE2 Pantoea 
agglomerans removed 64 ± 4% of the drug. This research shows the importance of the involved 
bacteria for the effectiveness of the removal of these drugs in a wastewater treatment p lant. A 
complete removal of pharmaceutical compounds from wastewater will stimulate water reuse, 
directing attention worldwide increasing requirements for clean and safe fresh water.  
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 INTRODUCTION:   
1.1  Background 
   In recent years, environmental emerging contaminants have rep resented a great challenge 
to the environmentalists and governmental agencies due to their numerous types, lower 
detectable levels, wide sp reading and potential toxic effects. In the past decade research work and 
scientific efforts related to these substances have been contributed for gaining more awareness 
from the public and calling for government actions to establish guidelines for better 
environmental p rotection. Three kinds of targets can be generally  defined as “emerging 
contaminants” in scientific researches, including new compounds and molecules that recently  
appeared and were not known before, existed contaminants with undiscovered environmental 
issues or emerging interests, new information on their environmental risks challenging our 
understanding of some heritage contaminants ( Desrosiers, Melanie, 2014). Currently , extensive 
array  of emerging contaminants has been increasingly  p robed, including pharmaceuticals and 
personal care p roducts, disinfection/treatment by -p roducts, perfluorinated compounds, 
fragrances, hormones, p lasticizers, flame retardants, nanoparticles, algal toxins and so on. 
Obviously , these chemicals can be found everywhere in our daily  life and are also app lied 
worldwide with huge consumption. Although they  are bringing to peop le great convenience and 
benefits, it’s necessary  to bear the risks resulting from their growing app lications. Potential 
carcinogenicity , rep roductive dysfunction and endocrine disrup ting influences are some major 
adverse effects on human health, associated with the emerging contaminants such as 
perfluorinated compounds (Elcombe et al., 2010; Fei et al., 2009; Fent, Weston, and Caminada, 
2006; Klaunig, Hocevar, and Kamendulis, 2012; Righi et al., 2012; Villanueva et al., 2015). 
Beyond the health concerns, these substances are entering the environment inevitably , not only  
sourced from the daily  use but also from the fields of healthcare, industry , transport, agriculture 
and so on (Lei et al., 2015). As a result, the impacts of emerging contaminants on the ecosystem 
are raising more environmental concerns. 
 
1.2  Wastewater treatment 
   Nowadays, more and more classes of emerging contaminants have been found in the 
aquatic environment all over the world. Most of these emerging contaminants are released into 
the environmental waters mainly  because of their incomplete removal in the sewage effluent via 
the WWTP. In recent years the p roblem of wastewater is becoming increasingly  acute and 
relevant throughout the world. In the course of economic activity , modern society  consumes all 
considerable quantities of water, most of which as a result becomes contaminated by  a wide 
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variety  of substances. 
  The pharmaceutical industry  has been increased significantly  in the last decade, 
p roducing thousands of metric tons annually  of diverse chemicals used in medicine, veterinary , 
agricultural p ractice, human health and cosmetic care, which have a wide range of 
pharmacological and toxicological p roperties (Ávila and García 2014; Products et al., 2004). As 
a result of pharmaceutical companies are p roducing different types of pharmaceutical p roducts at  
large scale worldwide and also p roducing complex non-biodegradable toxic wastes byp roducts 
and releasing untreated or partially  treated wastes in the environment in absence of strong 
regulations. These waste pollutants are contaminating all types of  water sources (Klaus, 2010). 
This leads to their p resence in wastewater due to disposal and excretion in ranges that can be 
between 50-90% of the initial amount, which in turn may  be unchanged or as metabolites 
(Daughton and Ternes, 1999; Williams, 2004) resulting from biotransformation into the body  and 
released through urine and/or feces and also through the removal of exp ired drugs that can enter 
directly  into the sewage sy stem (Daschner and Ku, 2015; Daughton and Ternes, 1999; Hirsch et 
al., 1999). During wastewater treatment p rocess through biodegradation or adsorp tion most of 
pharmaceutical compounds are not removed. WWTPs intendent to remove certain specific 
compounds such as biochemical oxygen demand, ammonia and phosphorous, through 
biodegradation or adsorp tion (Daughton, States, and Protection, 2016). However, during the 
wastewater treatment p rocess most of the pharmaceutical compounds are not removed. Thereby , 
they  are entering in the aquatic environment through treated wastewater. Since most 
pharmaceuticals are polar compounds, they  mostly  remain in water bodies in the environment 
rather than being adsorbed in river, lakes or sediments, which exp lain their frequent detection in 
surface or ground water (Daughton, 2016; Project Acronym, 2004). Therefore, aquatic organism 
have a toxicological risk considered as a highest.  
 1.2.1 Removal/treatment strategy 
  Because pharmaceutical compounds in the environment are currently  not regulated, 
scientists are finding nowadays the harmful impact for human health effect directly  related of the 
p resence of low-level of these substances in the environment. In order to p rotect water sy stems, 
the level of these compounds in the environment should be reduced, thereby  minimizing 
unp redictable long-term consequences. 
 
Mechanisms to achieve reduction of emerging pharmaceutical compounds: 
 Two main mechanisms can be used aiming the reduction of pharmaceutical emerging 
compounds in the environment. They  are: 
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1. Reduce source. It requires reduction of pharmaceutical drug use and p roper disposal of 
unused drugs. This will be difficult to achieve and requires a change from the point of view 
of society  as a whole, namely  by  the imp lementation of government rules to stimulate 
recycling p rograms and pharmaceutical guides. 
2. Removal by  wastewater treatment. As p reviously discussed most pharmaceutical compounds  
are not removed during routine wastewater treatment by  biodegradation and adsorp tion. 
Consequently , improved treatment technologies must be imp lemented to achieve effective 
removal of pharmaceutical drugs during the p rocesses of water treatment. 
 As a rule, ordinary  wastewater treatment is aimed to remove organic matter, suspended 
matter and nutrients in wastewater to reduce pollution. Therefore, WWTPs design parameters are 
usually  driven to reduce of biochemical oxygen demand, ammonia and phosphorous. A 
combination of physical, chemical and biological p rocesses is generally  used (Figure. 1.1.), 
consisting of the steps outlined below (Tchobanoglous et al., 2013). 
• Preliminary treatment. It consists on the removal of coarse particles and materials in raw 
wastewater entering the treatment p lant, by  removing grit or coarse screening. 
• Primary treatment. Removable of organic and inorganic solids by  sedimentation, while 
materials that float are removed by  skimming. 
• Secondary treatment. Primary  drains are treated at this stage to remove residues of organic 
and suspended matter biologically , using usually  aerobic microorganisms (most of which are 
bacteria). The most commonly  used secondary  treatment p rocess is activated sludge, in 
which the p rimary  drains and microorganisms are actively  mixed in a tank by  the aid of 
aeration devices that supply oxygen to microorganisms. 
• Sludge processing. Precip itated solids from the p rimary  and secondary  treatment steps are 
most often treated with anaerobic digestion. In these biological p rocess , anaerobic and 
facultative bacteria metabolize the organic material, which leads to a more stable sludge with 
enhanced dewatering characteristics. Methane gas p roduced during anaerobic digestion can 
be extracted as an energy  source and used locally . 
Figure 1.1. Schematic of conventional wastewater treatment plant. 
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1.3 Primary concerns 
1.3.1 Antidepressants 
  Antidep ressants are p sychoactive pharmaceuticals and are p rescribed to treat a variety  of 
p sychological distresses such as dep ression, anxiety , bulimia and obsessive-compulsive disorder. 
Antidep ressants are one of the most commonly  p rescribed drugs. These drugs are frequently  
p rescribed long-term, with 60% of patients taking these pharmaceuticals for over 2 years. With 
such abundant and persistent use, antidep ressants have become potential endocrine disrup ting 
chemicals (EDCs) as they  enter in the environment following improper disposal and insufficient 
metabolism and ineffective removal from wastewater treatment p lants. Antidepressants are being 
reported in concentrations up  to several ng-mg/L in raw sewage, effluent from sewer treatment 
facilities, rivers downstream of such facilities and have been detected in drinking water in trace 
levels (Fachini et al., 2009; Jjemba 2006). 
1.3.2 Estrogenic compounds 
 Estrogenic compounds rep resent the second concern due to their effect on the fertility  and 
development (endocrine disrup tion) of aquatic organisms at ng/L concentrations. This has been 
greatly  attributed to the increased use of oral contracep tives and their subsequent disposal or 
excretion (Daughton and Ternes, 1999). Although a reduction in estrogenic activity  has been 
measured as a result of wastewater treatment, some estrogenicity  persists in the effluent being 
discharged to surface waters.  
 Several studies (references of those studies) have investigated the impacts of estrogenic 
WWTP effluent on fish populations and discovered that they  are sensitive to low levels of 
estrogens (≤ 50 ng/L). The collection of white sucker fish immediately  upstream and 
downstream of a WWTP treated effluent discharge site showed that the frequency  of male fish 
downstream (17-21%) was half that of the upstream collection (36-46%). The same study  found 
that 18% to 22% of the total downstream fish population collected were intersex (both male and 
female rep roductive organs), while there were none upstream of the effluent discharge (Gray  et 
al., 2008). There is no direct or conclusive evidence that the same trends are taking p lace in the 
human population, there is growing concern that the declining numbers of healthy  baby  boys 
being born, the increase in male genital defects, and DNA-damaged sperm p roduced by  
“healthy” males are a result of the p resence of estrogens and other endocrine disrup tors in our 
environment to which we are exposed. It has been p roposed that exposures during fetal/neonatal 
life may  lead to p roblems in adult rep roductive functions and fertility  (Sharpe and Skakkebaek, 
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1993) and that special care should be taken regarding exposures of p regnant women to endocrine 
disrup ting compounds.  
1.4  Pharmaceutical compound studied  
 There are a huge number of pharmaceutical compounds used in all over the world. It 
would be impossible to study  every pharmaceutical compound used. Therefore, it is necessary  to 
establish a set of criteria in order to determine which compounds to focus on: 
• Pharmaceutical compounds that are often detect in WWTP and surface waters; 
• Pharmaceutical compounds that are not biodegradable during the conventional biological 
wastewater treatment p rocess; 
• Pharmaceutical compounds that are commonly  p rescribed and used.  
         FLX and its metabolite NFLX (selective serotonin re-up take inhibitor) and synthetic 
estrogen, p resent in oral contracep tive p ills, 17α-ethiny l estradiol (EE2) were considered and 
mainly  selected as models using the following criteria. Physical and chemical p roperties for 
chosen pharmaceutical compounds outlined below (Table 1.) 
Table 1. Selected chemical and physical p roperties of the pharmaceutical compounds used in this  
study .  
Compound 
name  
Biological 
activity 
Chemical 
structure 
Chemical 
formula 
Molar 
mass 
(g/mol) 
pKa 
Water 
solybilyt
y (g/L) 
Fluoxetine 
(FXT) 
Antidep ressa
nt 
 
C17H18F3NO 309 9.8 0.0017 
Norfluoxetine 
(NFLX) 
Antidep ressa
nt 
 
C16H16F3NO 295 9.77 0.0092 
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Ethiny lestradiol 
(EE) 
Birth control 
 
C20H24O2 296 10.33 0.000011 
1.4.1 FLX 
 Fluoxetine (commonly  named as Prozac®) is an antidep ressant which is usually  used to 
treat dep ression, obsessive compulsive disorder, panic attacks and certain eating disorders, and 
can be used to alleviate the symptoms of p remenstrual dysphoric disorder. Chemical structure of 
FLX and NFLX illustrated below (Figure 1.2). 
 
Figure 1.2. Chemical structure of the enantiomers of FLX and NFLX. 
Fluoxetine is part of a class of selective serotonin reup take inhibitors that increase the amount of 
serotonin in the brain to help  maintain mental balance (Wenthur, 2016). Side effects in humans’ 
body  may  include nausea, nervousness, insomnia, headache, tremor, anxiety , and drowsiness. 
Fluoxetine is a white cry stalline powder, odorless, which dissolves easily  in methanol and 
ethanol but it is insoluble in toluene, cyclohexane and hexane. Fluoxetine is comp letely  and 
easily  absorbed in the human gastrointestinal tract. FLX is extensively  metabolized to NFLX and 
several other metabolites such as FLX-glucuronide, NFLX-glucuronide, para-
trifluoromethy lphenol and hippuric acid. The p rincipal metabolite NFLX, is formed by  N-
demethy lation of FLX. The potency  and selectivity  of NFLX selective serotonin reup take 
inhibitors activity  is similar to that of the parent drug (Krout et al., 2016). Recent research 
performed by   (Silva et al., 2014) have shown that most FLX and NFLX, enter the aquatic 
8 
 
environment via untreated communal wastewater. Both FLX and NFLX have been detected in 
wastewater and receiving waters at levels ranging from ng/ L to mg/L. Fluoxetine were detected 
in mean detected levels of 127.97 and 100.4 ng/L in influent samp les. Furthermore, they  were 
found in the tissue of fish collected near municipal wastewater discharges  (Silva et al., 2014). 
Both FLX and NFLX remain biochemically  active in the environment and can have marked 
effects on the morphology , physiology  and behavior of different species .  FLX has one chiral 
carbon in its structure and as a result it exists in two enantiomeric forms as (S)-FLX and (R)-FLX 
(Figure 2). Similarly , NFLX exists in two enantiomeric forms as (S)-NFLX and (R)-NFLX. 
Enantiomers of the same drug have identical physicochemical p roperties but may  differ in their 
biological p roperties. Metabolism of FLX was found to be enantioselective in humans, with the 
(R)-enantiomer being metabolized faster than (S)-enantiomer (Caccia, Farmacologiche, and 
Negri, 1998). 
1.4.2 EE2 
 Oral contracep tive component EE2 is the most commonly  p rescribed estrogen drug, the 
molecular structure (C20H24O2, M W=296.403 g/mole) is illustrated in Figure 3. is a synthetic 
estrogen which is excreted in urine and feces of individuals and isn’t completely  removed during 
wastewater treatment p rocess (Owen and Jobling, 2012).  
 
Figure 1.3. Chemical structure of the synthetic estrogen EE2. 
 
  Approximately  12 kg of EE2 was sold per year in pharmacies across Canada between 
2005 and 2010 (Fischer et al., 2018);  the estimated yearly  consumption in Poland, 
app roximately  8 kg in 2000, in  Spain, 12 kg in 2003, and significantly  while in Germany , 48 kg 
in 2001 (Fent, Weston and Caminada, 2006). EE2 has been detected in wastewater treatment 
effluents worldwide at concentrations up  to 62 ng/L (Amuelian and Umpter, 2009; Choubert et 
al., 2009) and is one of the most important contributors to the estrogenicity  measured in WWTP 
effluents. Its p resence in WWTP effluents indicates that it is not completely  removed during 
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conventional wastewater treatment. A recent research were investigating pharmaceutical 
compound removal in different WWTPs found that the average removal of EE2 was 65% ± 15% 
(Choubert et al., 2009). Since adsorp tion has been found to be minimal this suggests that EE2 is 
not fully  biodegraded during secondary  treatment (activated sludge). Studies investigating the 
biodegradability  of EE2 using activated sludge samp les have had conflicting results. While it 
was p redicted to be partially  removed via biodegradation by  one study , others observed from 
100% EE2 removal  to none at all (Fujii et al., 2002; Hashimoto and Murakami, 2009; Weber et 
al., 2005). 
 However, extensive research has already  been carried out investigating EE2, there is still 
indeterminate information regarding its biodegradability , especially  the relative change in 
toxicity  and estrogenicity  and the identification of by -products. 
1.5 Summary of literature review  
 There is growing disturbance caused by  the p resence of pharmaceutical compounds in the 
environment due to their extensive use, excretion/disposal, and incomplete removal during 
wastewater treatment p rocess. The potential develop ment of antidep ressant and the endocrine 
disrup tion of aquatic organisms are two of the p rimary  concerns. This has led to increased 
research investigating their removal with many  studies focused on their biodegradability  during 
secondary  wastewater treatment using activated sludge samp les. This study  aims to defined 
bacterial isolates from activated sludge samp les which consist of variable microbial populations. 
It was possible to see that the isolated bacteria were able to partially  biodegrade the drugs under 
study . This study  also exp lores the effect on the biodegradability  of FLX and EE2 and the 
identification of by -products resulting from their biodegradation with bacteria isolates. 
1.6 Aim and objectives  
 The broad aim of this study  was to investigate the biological removal of FLX and EE2 
using bacterial isolates from activated sludge collected from WWTP (Faro, Portugal) which 
showed the ability  to grow in p resence of the drugs.  
Objectives were as follows: 
1. Selection of bacteria isolates from the microbial community  from activated sludge 
samp le with ability  to grow in the p resence of FLX and EE2. 
2. Sequencing the bacterial 16S rRNA gene. 
3. Identification of bacterial isolates by  16S rRNA from the obtained bacteria isolates. 
4. Determine the p resent bacteria isolates app ly ing the resulting sequence data and identify  
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them using BioEdit software. The obtained sequences compare with the data in the NCBI 
ribosomal DNA sequence (Bacteria and Archaea) database by  using the NCBI Blast 
p rogram. 
5. FLX and EE Biodegradation assays in liquid culture. 
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2. MATHERIALS AND METHODS 
2.1 Chemicals 
 The following reagents were purchased from Panreac (Barcelona, Spain): potassium 
hydrogen phosphate (K2HPO4) and potassium dihydrogen phosphate (KH2PO4), manganese(II) 
sulfate (MnSO4), calcium chloride (CaCl2), sodium chloride (NaCl), magnesium chloride 
hexahydrate (MgCl2·6H2O), zinc sulfate (ZnSO4·7H2O), ethy lenediamine tetraacetic acid 
(EDTA), bacteriological agar, ammonium molybdate tetrahydrate ((NH4)6Mo7O24·4H2O). 
Ringers solution and pep tone were obtained from VWR Prolabo Chemicals (Leuven, Belgium). 
Ammonium phosphate dibasic (NH4)2HPO4 was obtained from Acros organics (Geel, Belgium). 
Glucose, Nutrient Broth for general cultivation, Plate Count Agar (PCA) were purchased from 
Himedia Laboratories Pvt. Ltd. (India). Fluoxetine hydrochloride (99% purity ), 17α-
ethiny lestradiol (98% purity ) were purchased from Sigma-Aldrich (Hamburd, Germany). 
Norfluoxetine hydrochloride (≥95% purity ) was purchased from Sigma-Aldrich (Buchs, 
Switzerland). Acetonitrile (ACN) of HPLC grade was supplied by  Merck (Germany). Phosphoric 
acid (85% purity ) was supplied by  VWR Prolabo Chemicals (Fontenay -sous-Bois, France). 
 
2.2 Inoculum source and preparation   
 Sludge samp le collected from the oxidation ditch (aerobic p rocess) of the Northwest 
WWTP of Faro (Portugal) was used to obtain bacteria in order to test their resistance and ability  
to degrade FLX, its metabolite NFLX and EE, under aerobic conditions.  
1 g of sludge was p reviously  washed twice with Ringer´s solution and then centrifuged to discard 
the supernant that may contain the carbon sources. 
2.3 Enrichment of bacteria from sludge 
 Successive dilutions p rotocol was performed with the washed pellet incubated in 9 mL of 
0.1% (w/v) peptone water at 28 °C for 2 hours. Dilution series were made in 15 mL p lastic tubes  
with 9 mL nutrient broth, by  transferring 1 mL from the batch culture to fresh Nutrient Broth, 
followed by  transferring 1 mL of the latter into 9 mL fresh nutrient broth and repeated several 
times to achieve concentration 10-7 mg/ml. 
2.4 Screening and isolation of resistant bacteria to FLX and EE2. 
 0.1 mL of the microbial dilution series was sp read on the solid agar p late with a s terile 
p lastic rod. Preparation of solid media (solid p late cultures (15 g/L agar) with mineral salt 
medium (MSM), which was composed by 0.5 g/L K2HPO4, 0.5 g/L KH2PO4, 0.01 g/L NaCl, 0.2 
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g/L MgCl2.6H2O, 0.02 g/L CaCl2, 0.0004 g/L ZnSO4, 0.78 g/L CoCl2.6H2O, 0.0003 g/L MnSO4, 
0.01 g/L of ethy lenediamine tetraacetic acid (EDTA) and 0.0004 mg/L (NH4)6Mo7O24.4H2O), 
with a nitrogen source of 1 g/L (NH4)2HPO4 and a carbon source: 10 g/L glucose (used as 
positive control) and 50, 100 mg/L FLX and 50 mg/L EE2 as only  carbon sources. MSM was 
autoclaved at 120 °C for 45 min and cooled to room temperature before the addition of FLX and 
EE2. The stock solution of FLX/EE in concentration 1000 mg/L was performed by  dissolving 10 
mg of drug in 100 μL of methanol and fulfilled with 10 mL of milliq-Q water. The 
pharmaceuticals FLX and EE2 were added using a PES sy ringe filter of 0.2 μm pore size from 
VWR (Leuven, Belgium) to make the tested drug concentrations: 50 mg/L and 100 mg/L for 
FLX, 50 mg/L for EE2. The agar p lates were p laced upside down to p revent condensation on the 
agar and incubated in the dark at 28ºC for 24, 48 and 144 hours (depending on bacterial growth). 
 A screening of resistant bacterial isolates colonies was done after 24, 48 and 144 hours to 
select and isolate resistant bacteria colonies for further tests of drugs biodegradation. The 
bacterial isolates rep resenting morphologically  (p igmentation, shape, size, elevat ion, margin) 
different colonies and/or similar morphotypes with ability  to grow in the p resence of the drugs 
were p icked for further identification and to perform pharmaceuticals biodegradation 
experiments. Bacterial isolates were stored in 30% of glycerol at -20 °C. 
2.5 Identification of pharmaceutical resistant bacteria. 
 To identify  the bacterial isolates able to degrade the drugs under study , biomass was 
produced for DNA extraction.  For biomass p roduction, 100 μL of glycerol culture was poured 
onto solid PCA growth medium at 23.5 g/L and the sp read p late method was performed with a 
sterile p lastic rod. Cultures were incubated at 28 °C in the dark for 48 hours. DNA was extracted 
from each isolate bacterial culture with the E.Z.N.A.® Soil DNA Kit. DNA extraction steps for 
each sub-sample were as follows for p rotocol p rovided by  manufacturer:  
Step  1: 100 mg of samp le added to a Disrup tor Tube and 725 µL SLX-Mlus Buffer. Vortexed at 
maximum speed for 3-5 minutes to ly se samp les. Centrifuged at 500 x g for 5 seconds to remove 
drops of liquid from the lid. 
Step  2: Was added 72 μL DS Buffer. Vortexed to mix thoroughly . Incubated at 70°C for 10 
minutes. Briefly  vortexed the tube once during incubation.  Centrifuged at 10,000 x g for 5 
minutes at room temperature. 
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Step  3: 400 µL supernatant were transferred into a new 1.5 mL microcentrifuge tube and added 
135 µL chilled P2 Buffer. Vortexed to mix thoroughly  after p laced on ice for 3 minutes. 
Centrifuged at maximum speed (≥13,000 x g) for 1minute. 
Step  4: Carefully  transferred the supernatant to a new 1.5 mL microcentrifuge tube after were 
added 200 μL cHTR Reagent. Vortexed to mix thoroughly , let sit at room temperature for 2 
minutes. Centrifuged at maximum speed for 1 minute. 
Step  5: Transferred cleared supernatant (~500 µL) to a new 1.5 mL microcentrifuge tube.  
Step  6: Were added an equal volume XP1 Buffer. Vortexed to mix thoroughly . 
Step  7: HiBind® DNA Mini Column were insert into a 2 mL Collection Tube and were 
transferred up  to 700 µL sample from Step  6 to the HiBind® DNA Mini Column. Centrifuged at  
10,000 x g for 1 minute at room temperature.  
Step  8: The Step  7 were repeated until all the ly sate from Step  6 has passed through the HiBind® 
DNA Mini Column. 
Step  9: 500 µL HBC Buffer were added. Centrifuged at 10,000 x g for 1 minute.  
Step  10: HiBind® DNA Mini Column were transferred into a new 2 mL Collection Tube and 
added 700 µL DNA Wash Buffer. Centrifuged at 10,000 x g for 1 minute.  
Step  11: Step  10 was repeated for a second DNA Wash. Buffer wash step. 
Step  12: Centrifuged the emp ty HiBind® DNA Mini Column at maximum speed for 2 minutes at 
room temperature. 
Step  13: HiBind® DNA Mini Columns were transferred into a clean 1.5 mL microcentrifuge 
tube. and was added 50-100 µL Elution Buffer heated to 70°C directly  onto the center of 
HiBind® matrix. Let sit at room temperature for 1-2 minutes. Centrifuged at maximum speed for 
1 minute. 
Step  14: The filtrate was taken from Step  13 and p laced onto the center of the same HiBind® 
DNA Mini Column used in the p rocedure. Let sit at room temperature for 1 minute. Centrifuged 
at maximum speed for 1 minute. 
Step  15: Stored eluted DNA at -20°C. 
 The concentration and quality  of eluted DNA was determined using a NanoDrop  
spectrophotometer Thermo Scientific 3300 for further amp lification of the DNA extracted 
through the polymerase chain reaction (PCR). PCR amplification concerned the creation of 
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rep licates of DNA segments – of a region of the 16S rRNA marker gene as outlined in Figure 
2.1. 
  
Figure 2.1 a) Basic scheme of PCR p rocess; b) 2720 Thermo Cycler used. 
  For the PCR amplification of the bacterial 16S rRNA gene conserved region the 
following universal p rimers were used: 8F (forward) 5'-AGAGTTTGATCCTGGCTCAG-3'/ 
1492R (reverse) 5'-TACCTTGTTACGACTT-3'. The final volume of 50 𝜇L PCR mixture 
contained 5 𝜇L Green Taq Buffer, 2 𝜇L of each p rimer, 1 𝜇L deoxynucleoside triphosphate 
(dNTP), 0.2 𝜇L Taq DNA polymerase, 37.8 μl Molecular Biology  Water and 2 𝜇L temp late 
DNA (sample). 5 μL of 1 kb NZYDNA Ladder VII was used as molecular marker to estimate, 
by  comparison, the size of the DNA fragments under analy sis. The amp lifications were 
performed on the thermal cycler 2720 using the following conditions: initial denaturation at 94 
°C for 3 minutes, followed by  35 cycles of 94 °C for 1 minute (denaturation), 57 °C for 30 
seconds (p rimer annealing) and 72 °C for 2 minutes (elongation), and final elongation at 72 °C 
for 5 minutes. The gel electrophoresis was performed using 5 μL of amp lified PCR p roduct 
which was added with 2 μL of loading dye buffer x6 containing blue and orange bromophenol 
dyes G on an agarose gel (1% agarose, Tris- 1% Acetate-EDTA (TAE)). 3 μL of DNA safe 
SYBR (NZYtech) was added to the agarose. 5 μL of 1 kb NZYDNA Ladder VII was used as 
molecular marker to estimate, by  comparison, the size of the DNA fragments under analy sis. Gel 
migration was carried out at 100 V for 1.5 hour. 
 Direct sequencing of the PCR p roducts was performed by  the Sanger method. 
 DNA sequencing and fragment analy sis was performed in a Genetic Analysis 3130xl 
sequencer (App lied Biosystems, USA). The results were obtained by  Sequencing Genetic 
Analysis Software, p rovided by  CCMAR's Molecular Biology  p latform.  
 Obtained sequences were analyzed using BioEdit software. The obtained sequences  were 
compared with the data in the NCBI ribosomal DNA sequence (Bacteria and Archaea) database 
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by  using the NCBI Blast p rogram, and the strain information with the largest similarity  to the 
sequence of the tested bacteria was obtained, giving the taxonomic ident ity . The results were 
compared with RDP data based. 
 Biochemical tests were performed, catalase activity  was determined by  observing bubble 
p roduction after the app lication of 3% (v/v) hydrogen peroxide solution, a positive reaction is 
indicated by  the p roduction of bubbles. Oxidase activity  was evaluated with Microbact oxidase 
strip s (OXOID). 
  gram staining p rotocol was performed, and p reparations were observed on a light 
microscope (Leica Microsystems). 
 
2.6 Pharmaceuticals biodegradation assays  
 Liquid cultures were used to study  the biodegradation of the drugs by  the bacterial 
isolates. After bacterial isolates identification, the further experiments were carried out in liquid 
medium using the MSM performed as described above supplemented with a nitrogen source of 1 
g/L of (NH4)2HPO4 and a carbon source: 10 g/L glucose (positive control) or 15, 20 or 50 mg/L 
of the drug. Negative controls only  with the drug and in the absence of the bacterial isolates were 
performed. The bacterial isolate cultures were incubated at 28 °C and shake at150 rpm in the 
dark. Sampling was done after 24 h, 48 h and 168 h. The assays were performed in trip licate. 
2.7 Measurement of the growth of bacterial cells 
 Growth of the bacterial cells was monitored before samp ling by  measuring the op tical 
density  (OD) at 600 nm using a Hach-Lange™ DR 2800 UV/visible spectrophotometer.   
2.8 Biodegradation of FLX by HPLC Analysis 
 To analy se the biodegradation of FLX an HPLC analy sis was performed using an 
isocratic method with a mobile phase consisted of ACN:trimethy leamine (60:40, v/v) and a pH 
adjusted to 2.5 with orthophosphoric acid (85%) using a flow rate of 1.0 mL/min and a total run 
time of 10 minutes with the column maintained at room temperature. The injection volume was 
20 µL and a wavelength of 226 nm was used for detection.  
 All samp les were collected and filtered with 0.2 μm polyp ropy lene (PP) sy ringe filters 
from VWR (Leuven, Belgium) and stored at 4 °C before chromatographic analy sis. Fluoxetine 
was analyzed using a modular Advanced Scientific Instrument KNAUER HPLC system with a 
Smartline UV detector 2600 Smartline Manager 5000 (Berlin, Germany). The output signal was 
monitored and integrated using ClarityChrom® software. The compounds were separated using a 
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reversed phase SpherisorbC18 column (250 × 4.6 mm, 5 µm particle size) - Silica technology  
connected to a Guard Column Xbridge-C18 column (4.6 × 200 mm, 5 µm particle size), both 
purchased from Waters Corporation (Milford, MA, USA). 
  
2.9 Biodegradation of EE2 - Analysis of EE2 by GC-MS 
 2.9.1 Derivatization of EE2 
 To determine the concentration of EE2 four samp les were p repared in trip licates. For the 
analy sis derivatization of EE2 was required. Before derivatization all samp les were lyophilized 
and resuspended in methanol. For derivatization 50 μL of each samp le were taken in 2 mL glass 
vials. In each samp le, the solution was dried under gentle nitrogen stream after the addition of 50 
μL of EE2. Then 50 μL of solution: 280 µL of MSTFA, 11.2 mg NH4I, 
16.8 µl betamercap toethanol with MSTFA (1/9) were p ipetted into the vials, respectively . 
Estrogenic hormones should be sily lated using MSTFA which lead to the formation of 
trimethy lsily l (TMS) and tert-buty ldimethy lsily l (TBS) due to the cataly tic effect of NH4I, both 
the hydroxy l and the keto functional groups of EE2 (on carbons 3 and 17, respectively ) could be 
converted to TMS ethers. The introduction of a sily l group s gives derivatives of enhanced 
volatility , making the derivatives suitable for analy sis by  gas chromatography . Prior to 
derivatization, the total volume in every  vial was 100 μL. The vials were sealed and the solution 
was heated on a bath at 60 0C for 30 min. Derivatized samp les were then analyzed by  GC–MS. 
 The column was a Restek-Rxi® - 5 Sil MS (Crossbond®, similar to 5% dipheny l/95% 
dimethy lpoly siloxane) 30-meter, 0.25 mm ID, 0.25 µm df). Instrument parameters were as 
follows: Injection volume 1 µL, injector temperature, 250 ºC in mode sp litless , oven temp . 
programming was initial temperature 160 ºC, hold for 2 min 9 ºC/min to 260 ºC, hold for 5 min 
and 260 ºC to 300 ºC at 20 ºC/min hold for 5 min at final temperature, flowrate 1 mL/min, 
transfer line 250ºC, source 220ºC, carrier gas helium.  External standards of EE2 at five different 
concentrations from 1 to 12 𝜇g/mL were used for calibration curve. 
2.10 Statistical analysis 
 Experiments were carried out in trip licate and all values were exp ressed as 
means ± standard deviation. The data for degradation of FLX and EE2 were analyzed using a 
one-way  analy sis of variance ANOVA (Single Factor) tests using Excel Data Analysis Tools. 
The statistical analy ses were performed with p-value less than 0.05 which was considered 
statistically  significant. 
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3. RESULTS AND DISCUSSION 
3.1 Characterization of bacterial isolates 
 Selection and isolation of resistant bacteria colonies capable to grow in the p resence of 
the FLX and EE2 under study  was performed. The bacterial isolates with ability  to grow in the 
p resence of both drugs were selected by  colony  morphotypes. The identification and 
classification of colony  morphotypes were carried out following five different parameters: 
colony  size, form, color, texture and margin, to assess colony  morphotypes according to Table 
2.1. After 3 days, the colony  types most frequently  seen were smooth, opaque, with a regular 
circular or slightly  irregular undulated margin, from transparent white to transparent yellow 
colonies (thus making it difficult to identify  because of the very  small size and very  similar 
colors), which appeared in isolates 1, 2, 3, 4, 5, 7, 8, 11, 12 and 13 (Table 2.1). All isolates 
appeared to remain as domed colonies, while isolates 2 and 8 tended to become opaque and 
transparent or semitransparent color which turned into a darker or more yellowish color over 
time. Besides p roducing the above-mentioned colony  phenotypes, isolates 4 and 13 generated 
smooth, opaque colonies with irregular margins. Isolates 1, 5, 11 were particularly  noted for 
p roducing smooth, opaque colonies with regular circular margins. Isolates 3, 7 and 12 did not 
behave like the rest of isolates because their growth was faster, appearance was smooth, and the 
colonies were bigger (Table 2.1). In general, although not all colonies reached a few millimeters 
in diameter, some of them were so tiny  and barely  visible, smooth transparent colonies 
consistently  grew at a slower rate. The colonies less than 1 mm in diameter were classified as a 
tiny ; small colonies reached more than 1 mm and big colonies were the ones with more than 
3mm in diameter. 
Table 2.1. Colony  characteristics and classification of the bacteria isolated from the different 
drug concentration.  
Isolate 
Drug 
concentratio
n 
Colony morphotype Size 
1 50 FLX Smooth, opaque, regular, milky Small 
2 50 FLX Smooth, opaque, transparent, regular, white/yellow Small 
3 100 FLX Smooth, opaque, irregelar, beige Big 
4 100 FLX Smooth, opaque, irregular, beige/yellow Tiny 
5 100 FLX Smooth, opaque, regular, beige/yellow Small 
7 100FLX Smooth, opaque, irregular, beige Big spread colony 
8 50 EE Smooth, semitransparent, regular, creamy/beige Tiny 
11 50 EE Smooth, opaque, regular, beige/yellow Small 
12 50 EE Smooth, opaque, regular, beige/yellow Big 
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13 50 EE Smooth, opaque, irregular, yellow/white small 
 
 All the strains were grown on the PCA, to increase the number of colonies for further 
DNA extraction illustrated in Table 2.2. 
Table 2.2. Biomass p roduction step : a) concentration 50 mg/L of FLX; b) concentration 100 
mg/L of FLX; c) concentration 50 mg/L of EE2. 
a) 
 
b) 
 
50 FLX 50 FLX
100 FLX 100 FLX
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c) 
 
   
 3.2 Identification of bacterial isolates   
 In the p resent work, 16S rRNA gene sequencing was performed for bacterial 
identification. 16S rRNA gene, a conserved region, sequence is a reliable method to identify  
bacterial strains from environmental samp les. Bacterial identification results were obtained by  
BLAST analy sis using firstly  NCBI database and then RDP database, in order to compare 
accuracy  of identification.  Concerned bacteria were identified at the genus level, and for each 
isolate, both NCBI and RDP database gave the same result. The identification was performed by  
introducing the contig0 sequences in the NCBI database and results were exp ressed as similarity  
score (%) between our isolates and identified isolates in the database where there was matching 
among 16S rRNA sequences. Isolates were identified based on maximum obtained similarity  
scores that were mostly  above 95%, which indicates good matching and reliability . NCBI 
database was chosen due to its advantage to identify  bacterial isolates to the species level, which 
is not possible with the RDP database. Results revealed that isolate 1 corresponded to 
50 EE 50 EE
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Pseudomonas putida with similarity  score of 99.21%; isolate 2 was identified as Enterobacter 
ludwigii with 99.01 % similarity  score; isolate 3 belonged to Pseudomonas nitritireducens with 
similarity  of 99.22%; isolate 4 corresponded to Alcaligenes faecalis with 98.28% of similarity ; 
isolate 5 was most similar to Pseudomonas aeruginosa with 99.42%; isolate 7 was identified as  
Pseudomonas nitroreducens with 98.01% similarity ; isolate 8 corresponded to Acinetobacter 
bouvetii with obtained similarity  score of 98.51%; isolate 11 was similar to Acinetobacter kookii 
(97.03%);  isolate 12 was identified as  Pantoea agglomerans (87.47%), and finally , isolate 13 
corresponded to species Shinella zoogloeoides  with similarity  score obtained of 97.34%. 
 All isolates identified using 16S rRNA gene sequencing are p rovided in Table 2.3. 
Contig0 sequences are p rovided in Appendix 1. 
Table 2.3. Identification of isolates from activated sludge using 16S rRNA gene sequencing 
using NCBI Blast database.   
 
Sample 
name 
From Specie (NCBI Blast) 
Query 
cover 
Ident 
Accession nº 
(NCBI Blast) 
1 50 FLX  
Pseudomonas putida strain 
NBRC 14164  
98% 99.21% NR_113651.1  
2 50 FLX  
Enterobacter ludwigii strain EN-
119  
100% 99.01% NR_042349.1  
3 100 FLX  
Pseudomonas nitritireducens 
strain WZBFD3-5A2 
99% 99.22% NR_133020.1  
4 100 FLX  
Alcaligenes faecalis strain NBRC 
13111 
100% 98.28% NR_113606.1  
5 100 FLX  
Pseudomonas aeruginosa strain 
DSM 50071 
97% 99.42% NR_117678.1  
7 100 FLX  
Pseudomonas nitroreducens 
strain NBRC 12694 
98% 98.01% NR_113601.1  
8 50 EE  
Acinetobacter bouvetii strain 
DSM 14964  
100% 98.51% NR_117628.1  
11 50 EE  
Acinetobacter kookii strain 11-
0202 
95% 97.03% NR_135727.1  
12 50 EE  
Pantoea agglomerans strain 
JCM1236 
99% 87.47% NR_111998.1  
13 50 EE  
Shinella zoogloeoides strain 
NBRC 102405 
90% 97.34% NR_114067.1  
 
 Comparing the culture, morphological and biochemical characteristics of isolates with the 
drug-degrading (FLX, EE2) p roperties, it was found that the isolates (1, 2, 3, 4, 5, 7, 8, 11, 12 
and 13) belonged to Pseudomonas, Enterobacter, Alcaligenes, Acinetobacter, Pantoea and 
Shinella genus.  
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 The biochemical tests, oxidase and catalase were performed on the Pseudomonas putida, 
Enterobacter ludwigii, Pseudomonas nitritireducens, Alcaligenes faecalis, Pseudomonas 
aeruginosa, Pseudomonas nitroreducens, Acinetobacter bouvetii, Acinetobacter kookii, Pantoea 
agglomerans, Shinella zoogloeoides. Biochemical tests were performed to help  on the 
identification of isolates and the results are shown in Table 2.4. In the biochemical test of the 
isolates (oxidase and catalase), different responses were observed and compared to ABIS 
ENCICLOPEDIA to confirm the verity  of the obtained results. 
 Table 2.4. Biochemical tests of six most successful bacterial isolates  
Isolate Bacteria  
Oxidase 
test 
Catalase 
test 
Gram 
stain 
Color Colony characteristics 
1 Pseudomonas 
putida  
 +    +   -  Light yellow Some strains may have 
oval shape 
2 Enterobacter 
ludwigii  
 -   +   -  Nonpigmented Slightly iridescent or flat 
with irregular edges 
3 Pseudomonas 
nitritireducens  
 +   +   -  Pale yellovish Occurring singly or in 
pairs 
4 Alcaligenes 
faecalis  
 +   +  -  
Transparent 
white 
Margin usually entire, 
flat to low convex, 
spreading irregular edge 
5 
Pseudomonas 
aeruginosa  
 +   +   -  Light green 
Produce diffusive 
fluorescent pigment, 
large, smooth with flat 
edges 
7 Pseudomonas 
nitroreducens 
 +   +   -  
Transparent 
yellowish Smooth, entire, raised 
8 
Acinetobacter 
bouvetii  
 -   +   -  Light beije Circular, convex, smooth 
and light opaque 
11 
Acinetobacter 
kookii  
 +   +   - Light yellow Circular, smooth, opaque 
with entire margin 
12 
Pantoea 
agglomerans  
 +   -   - Beije-yellow 
Smooth, more or less 
convex with entire 
margin 
13 
Shinella 
zoogloeoides  
 -   -   - white-yellow Smooth opaque with 
irregular margins 
 ‘+’ = positive reaction, ‘-‘= negative reaction. 
 These bacteria grew in the p resence of the mentioned drugs, which indicates that they  
were able to degrade the compound, using it as a carbon source. Both FLX and EE2 are aromatic 
organic compounds. These bacterial genera herein identified were already  described in literature 
as having ability  to degrade aromatic organic pollutants (Jame et al., 2014), hence it was 
expected that they  would be able to degrade FLX and EE2 used in this study .   
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Examples are: 
• Pseudomonas are regarded as one of the most common species of degrading bacteria 
which has ability  to degrade aromatic compounds due to their ability  to use more than 80 
different carbon sources(Fava, Armenante, and Kafkewitz 1995; Hinteregger et al., 
1992). The ability  of this species particularly  to utilize aromatic hydrocarbons has been 
reviewed (Jame et al., 2014). It was also able to use a wide diversity  of carbon energy  
substrates and this together with their ability  to rival effectively  with another bacteria 
(Fakhruddin 2011).  
 
• Enterobacter microorganisms are known to degrade a variety  of aliphatic and aromatic 
amides. Generally , this does not include acry lamide due to its inhibitory  effect on 
sulfhydry l p roteins and hence growth of microorganisms. However, there are excep tions 
in some bacteria. Acry lamide utilizing bacteria appear restricted to species within the 
limits of genera Enterobacter. Some study  reported the isolation and characterization of a 
novel acry lamide-utilizing microorganism Enterobacter from domestic wastewater. The 
potential of acry lamide and amides degradations by  this microorganism was also detected 
(Asano et al. 1982; Buranasilp  and Charoenpanich 2011; Hoffmann et al. 2005; Mejiaruiz 
et al. 2002; Shukor et al. 2009).  
 
• Alcaligenes genera were found as acry lamide-utilizing bacteria. Bacterial strains capable 
of complete degradation of acry lamide and subsequent use of acry lic acid as a substrate 
mostly  for growth are used for biological deactivation. Microbial cells Alcaligenes can 
consume acry lic acid as a carbon source and accumulate it. Several pathways of acry lic 
acid formation by  bacteria are investigated (Maksimova et al., 2018). Alcaligenes also 
have phenol-degrading potential. The strains secreted and accumulated a vast quantity  of 
phenol hydroxy lase in physiological phase, which ensured that the cells could quickly  
utilize phenol as a sole carbon and energy  source (Jiang et al. 2007). 
 
• Acinetobacter is characterized as phenol-degrading microorganisms (Liu et al. 2016). 
Some strains of this genus are known to have a biodegradation of a wide number of 
different pollutants, such as bipheny l and chlorinated bipheny l, amino acids (aniline), 
phenol, benzoate, crude oil, acetonitrile, and in the removal of phosphate or heavy  
metals. Several studies have focused on the biodegradation of phenol by  various 
microorganisms. Among different phenol degraders are several strains correspond to 
Acinetobacter which can use it as a sole energy  and carbon source (Briganti et al. 1997; 
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Wenthur 2016). It has also been reported that certain Acinetobacter strains can utilize 
bipheny ls including chlorinated bipheny ls. Furthermore, some Acinetobacter isolates 
from mixed cultures has p roven to have ability  at complete mineralization of 
monohalogenated bipheny ls (Shields, Hooper, and Say ler 1985). Strains of Acinetobacter 
have also been emp loyed for degradation of lignin and amino acids (Abdel-el-haleem 
2013; Buchan et al,. 2001; Kahng et al., 2002). 
 
• Pantoea have the potential contribution to remove polycyclic aromatic hydrocarbons. It 
has been demonstrated that Pantoea show a high biodegradation ability  for polycyclic 
aromatic hydrocarbons and strong toxicity  tolerant to strict environment such as various 
pH, salt, and different polycyclic aromatic hydrocarbons concentration. During the 
biotransformation p rocess such as adsorption/desorption can p lay a significant role in the 
bioavailability  of polycyclic aromatic hydrocarbons (Cai et al. 2011; Seo, Keum, and Li 
2009; Zhao et al., 2018). 
 
• Shinella have been reported to degrade the derivatives of 1H-1,2,4-triazole, such as 
triazophos, tebuconazole, ipconazole, p rop iconazole and nicotine. Ability  to degrade 
nicotine efficiently  via the different of a py ridine and py rrolidine pathways (Strain Hzn, 
2014). The main in this pathway  include 6-hydroxy -nicotine, 6-hydroxy -N-
methy lmyosmine, 6-hydroxypseudooxynicotine, 6-hydroxy -3-succinoy l-py ridine, and 
2,5-dihydroxypyridine. This strain is the first nicotine-degrading bacterium to be isolated 
from the genus Shinella. It is also shown degradation of the toxic pollutants, 4-
aminobenzenesulfonate (Hzn et al., 2016).  
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3.3 FLX degradation by bacterial isolates experiments: Pseudomonas 
putida, Enterobacter ludwigii, Pseudomonas nitritireducens, Alcaligenes 
faecalis, Pseudomonas aeruginosa and Pseudomonas nitroreducens in liquid 
cultures. 
 The growth of the obtained bacteria (Pseudomonas putida, Enterobacter 
ludwigii,Pseudomonas nitritireducens, Alcaligenes faecalis, Pseudomonas aeruginosa and 
Pseudomonas nitroreducens) in MSM containing FLX is p resented in Figure 3.1.a and 3.1.b. 
The positive control (bacteria in p resence of glucose only , without FLX) was done to monitor the 
bacterial growth and results showed in Figure 3.2. In addition to this, all the flasks were always 
stored in dark p lace to p rotect from light and p revent degradation of FLX, since it is an aromatic, 
photosensitive compound. 
 
a) 
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b) 
 
 
Figure 3.1. Growth pattern of the isolates (Pseudomonas putida, Enterobacter ludwigii 
Pseudomonas nitritireducens, Alcaligenes faecalis, Pseudomonas aeruginosa and Pseudomonas 
nitroreducens) in MSM in the p resence of (a) 20 and (b) 50 mg/L FLX, respectively  at 28°C for 
168 h. 
 
 
Figure 3.2. Growth pattern of the isolates (Pseudomonas putida, Enterobacter ludwigii 
Pseudomonas nitritireducens, Alcaligenes faecalis, Pseudomonas aeruginosa and Pseudomonas 
nitroreducens) in MSM in the p resence of glucose 10 mg/L at 28°C for 168 h. 
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 All the bacteria isolates studied grew in the p resence of 20 mg/L and 50 mg/L FLX. For 
the concentration of 50 mg/L was used four out of six bacteria based on their better degrading 
p rofile at 20 mg/L. FLX At the concentration of 20 mg/L FLX, the maximum bacterial growth 
(OD600) observed for most of the isolates, excep t for Pseudomonas nitritireducens and 
Pseudomonas nitroreducens, was greater than 0.02 (0.021 ± 0.002 to 0.0270 ± 0.0005). In the 
case of Pseudomonas nitritreducens and Pseudomonas nitroreducens, the maximum growth was 
observed at app roximately  0.0100 ± 0.0005. Bacteria which grew in the p resence of 50 mg/L of 
FLX, reached their maximum growth at op tical density  of 0.0250 ±  0.0006, excep t for 
Pseudomonas nitritireducens with the OD value of 0.0083 ±  0.0005. In addition, the percentage 
of FLX removal achieved by  each bacterial isolate was also calculated (Table 2.5.).  
Table 2.5. Summary  of results for FLX bacterial isolates: maximum growth (op tical density  
measured at 600 nm) and percent FLX removal at (a) 20 mg/L FLX and (b) 50 mg/L FLX, after 
168 hours. 
a)  
Bacteria Maximum growth (OD600 
nm)c ± STDV 
FLX percent removal 
(%)d± STDV 
Pseudomonas putida  0.0270 ± 0.0005 39 ± 2 
Enterobacter ludwigii  0.028 ±  0.002 50 ± 1 
Pseudomonas nitritireducens  0.0100 ±  0.0005 50 ± 2 
Alcaligenes faecalis  0.027 ±  0.002 52 ± 2 
Pseudomonas aeruginosa  0.021 ±  0.002 53 ± 1 
Pseudomonas nitroreducens 0.0097 ±  0.0005 55 ± 1 
 
b)  
Bacteria Maximum growth (OD600 
nm) c ± STDV 
FLX percent removal 
(%)d± STDV 
Pseudomonas nitritireducens  0.0083 ±  0.0005 20 ± 2 
Alcaligenes faecalis  0.021 ±  0.003 21 ± 1 
Pseudomonas aeruginosa  0.0247 ±  0.0006 21 ± 1 
Pseudomonas nitroreducens 0.019 ±  0.001 21 ± 1 
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c) maximum op tical density  values measured at 600 nm (OD600) for each trip licate experiment 
d) maximum FLX percent removal of trip licate experiments (after 168 hours). 
 The experiment was monitored for one week and op tical density  was measured 
throughout the experiment to estimate the relative changes in bacterial growth. Increased 
bacterial growth in the p resence of FLX and an increase in FLX removal at the same time, 
indicated that (may  be a result of) these bacteria p referentially  consumed/used this drug as a 
readily  degradable carbon source, since the MSM did not contain any  other carbon source. 
Negative controls were also included in the experiment, containing only  MSM with FLX, but 
without bacterial isolates (Figure 3.1). In this case, FLX concentration remain the same or close 
to the initial value, as there were no bacteria that could use FLX as carbon source and degrade it. 
The positive controls were performed to monitor bacterial growth in addition of carbon source 
(glucose) (Figure 3.2). As it can be seen in Figure 3.2, in all cases the growth of isolates in 
p resence of glucose was better when compared to growth in p resence of FLX, with considerably  
higher OD values. This was expected, as glucose is a p referential carbon source for majority  of 
bacteria and when p resent in media, and it is assumed that microbes are always able to consume 
their p referred carbon sources (Buffing et al., 2018). The pattern of bacterial growth in 
p resence of 20 mg/L of FLX was similar to that of positive control (glucose), which indicates 
that FLX could be a p referential carbon source when p resent in the media. However, additional 
studies are needed to confirm this (e.g. to grow bacteria in p resence of both FLX and glucose).  
 To detect the FLX removal, HPLC analy sis was performed. The chromatogram and 
calibration curve are p resented in Appendix 2. One-way  ANOVA single factor test was app lied 
to compare the negative control (MSM with FLX without bacteria) and bacterial isolates 
growing in p resence of FLX. In the case of negative control, concentration of FLX remained 
app roximately  the same, dropp ing from initial 20 mg/L to 15 mg/L during 24 h, and remaining 
stable at the concentration from 15.7 to 16.01 mg/L until the end of experiment (Figure 3.3a) 
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a) 
b) 
 
Figure 3.3. Biodegradation of FLX by  Pseudomonas putida, Enterobacter ludwigii, 
Pseudomonas nitritireducens, Alcaligenes faecalis, Pseudomonas aeruginosa and Pseudomonas 
nitroreducens in MSM in the p resence of FLX at 20 mg/L (a) and 50 mg/L (b) at 28°C for 168 h. 
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 This indicates that the compound is extremely  stable and cannot be degraded naturally , which 
makes it hard to remove from the environment and/or wastewater. All the obtained bacterial 
isolates showed a statistical significance in terms of FLX degradation when compared to 
negative controls, with P values <0.05 at level of confidence of 95%. The growth curves 
(trip licates for each bacterium tested) corresponding FLX removals ± STDV are illustrated in 
Figure 3.3a and 3.3b, and a summary  of all the results of the individual bacteria experiments is 
outlined in Table 2.5. In biodegradation studies p reviously  performed by  our group  in what 
addressing the removal of FLX by  an aerobic community  isolated from aerobic sludge from the 
same wastewater treatment p lant, bacteria from Pseudomonas genus were also identified as the 
main FLX biodegrades (the results are not published yet). 
 The highest removal (>50%) of FLX at 20 mg/L, after 168 hours occurred in the p resence 
of Pseudomonas nitritireducens, Alcaligenes faecalis, Pseudomonas aeruginosa and 
Pseudomonas nitroreducens are 50 ± 2%; 52 ± 2%; 53 ± 1%; 55 ± 1% respectively . Promising 
results were also achieved with Pseudomonas putida, Enterobacter ludwigii, with FLX 
degradation little below 50% (39 ± 2; 50 ± 1%, respectively ).  As for the 50 mg/L concentration, 
after 168 h, the maximum FLX degradation achieved was 21 ±  1%. The following results were 
obtained by  isolates: Pseudomonas nitritireducens (20 ± 2%), Alcaligenes faecalis (21 ± 1%), 
Pseudomonas aeruginosa (21 ± 1%), and Pseudomonas nitroreducens (21 ± 1%) (Table 2.5.b). 
It is known that the genus Pseudomonas consists of bacteria capable of degrading organic 
compounds that are naturally  not easily  removed from the environment (Fathepure, 2014). This 
exp lains the fact that the best results in terms of FLX degradation (more than 50%) at 20 mg/L 
were obtained with bacteria from this genus (Pseudomonas nitritireducens, Pseudomonas 
aeruginosa and Pseudomonas nitroreducens). However, there was difference in degradation 
percentages between species of Pseudomonas genus. For example, Pseudomonas putida 
degraded only  39% of FLX, while the corresponding OD was the highest from all the 
Pseudomonas species (0.027). This suggests that FLX degradation does not depend on bacterial 
concentration (OD) but there are some other factors that influence this effect. Doubling time of 
species even in the same genus is not the same, some bacteria grow faster, therefore they  dep lete 
carbon sources faster, reach steady  state and stop  rep licating (Allen and Waclaw, 2018) 
Furthermore, as seen in Table 2.5, better degradation was achieved at 20 mg/L of FLX than with 
50 mg/L. This was expected, since the same bacterial inoculate was used for both concentrations. 
These results indicate that 50 mg/L could be toxic for this inoculum. There is possibility  that 
they  can achieve better degradation even at 50 mg/L, with additional source of carbon, for 
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example glucose, or they  need more contact time or maybe they  need to work as a consortium 
(increasing the initial inoculate).  
 For metabolites detection was done by  GC/MS, but due to analy tical p roblems they  were 
not detected. Many studies reported detection of its metabolite NFLX and some of them reported 
degradation of FLX in enantioselective manner. Barclay  et al., 2012 p resented the enantiomeric 
concentrations of FLX and its human metabolite NFLX, quantified in raw wastewater and in 
treated wastewater. Furthermore, the calculated enantiomeric fractions of the substances were 
found for FLX nor those for NFLX were significantly  different in the raw wastewater compared 
to the treated wastewater. Results showed the concentration of (S)-FLX was found to be higher 
than the concentration of (R)- FLX in both raw and treated wastewater. These results are 
different from other results p resented in the literature, which shows that the comparative 
concentrations of the enantiomers of a chiral active pharmaceutical ingredient might be 
significantly  different in wastewater samp les from different treatment sy stems (Barclay   et al., 
2012).  Regarding to the stereochemistry , FLX are degraded in an enantioselective manner, with 
p referential degradation of the (R)-enantiomer. The enantioselective quantification of FLX in 
raw and treated wastewater performed by  (Vasskog et al., 2006) revealed that (S)-FLX 
concentration was significantly  higher than the concentration of (R)-FLX. In recent research, 
using activated sludge as inoculum, both enantiomers were removed at about 80% in a non-
enantioselective manner (Ribeiro et al. 2014) into NFLX. Moreira et al., 2014 reported that the 
bacterial strain Labrys portucalensis degraded FLX in an enantioselective manner with the 
p referential degradation of the (R)-enantiomer. In this study  performed by  Moreira et al., 2014 
the absence of FLX degradation can be exp lained of the absence of indigenous FLX degrading 
organisms in the bioreactor biomass and thus, FLX was removed in a non-enantioselective 
manner. However, the cycle time could be too short for the biodegradation of the compound. It 
was demonstrated the degradation of enantiomers of the antidep ressant FLX and the possible 
formation of enantiomers of its active metabolite NFLX. The results show the degradation 
behavior of enantiomers of FLX sp iked in the wastewater effluent, for 46 days. The degradation 
was not enantioselective, and it is observed at 10 days for both enantiomers, from which the 
degradation performed until the day  21, being 65–75% of removal achieved until the day  13. 
Regarding the metabolite formation, the FLX biotransformation in its metabolite NFLX, was not 
observed (Ribeiro et al., 2014). Another study  (Moreira et al., 2014) reported  FLX in 
wastewater collected from a WTTP revealed that its influent was more enriched in (R)-
enantiomer than the effluent, it was suggested the p referential degradation of this enantiomer in 
wastewater It is necessary  to take into account that influent and effluent samp les do not 
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necessarily  rep resent the same stream of water and that the enantiomers in the influent does not 
obligatory  remain constant. The observed changes in enantiomers gave conclusive evidence of 
the enantioselective biodegradation by  the single bacterium, in which the (S)-enantiomer 
decomposition was slower than the (R)-enantiomer (Moreira et al., 2014). 
 
 
3.4 EE2 removal by bacteria isolates: Acinetobacter bouvetii, Acinetobacter 
kookii, Pantoea agglomerans and Shinella zoogloeoides in liquid cultures. 
 
 Four bacterial isolates grew in the p resence of EE2, which was demonstrated by  an 
increase in op tical density  measured at 600 nm (OD600) (Table 2.6.) in comparison to the 
negative control. ANOVA single factor test was app lied to identify  the significant difference 
between negative control and each bacterial isolate tested.  For all bacterial isolates, statistically  
significant effect on removing of EE2 was detected, with P values <0.05 at level of confidence 
of 95%. The highest op tical density  was observed in Acinetobacter bouvetii and Acinetobacter 
kookii with OD values of 0.553 ±  0.008 and 0.343 ± 0.006, respectively . EE2 degradation 
percentages achieved by  these two strains were 55 ±  3 and 48 ±  4% respectively . However, the 
highest EE2 degradation was detected in the case of Pantoea agglomerans (64 ±  4 %), which 
p resented lowest OD from all isolates, with values of 0.328 ±  0.001 after 168 hours. Once again, 
it was confirmed that drug degradation was not dependent on bacterial concentration, hence the 
low OD values for highest percentage of EE2 removal. Shinella zoogloeoides showed the lowest 
ability  to remove EE2 with corresponding removal percentages of 36 ± 4% and OD values of 
0.035 ±  0.001 (Table 2.6).  
 
Table 2.6.  Summary  of bacterial isolates results: maximum growth (op tical density  measured at 
600 nm) and removal percentage at 15 mg/L EE2, after 168 hours. 
Bacteria 
Maximum growth (OD 
600 nm) ± STDV 
EE2 precent removal (%) 
± STDV 
Acinetobacter bouvetii  0.553 ±  0.008 48 ± 4 
Acinetobacter kookii  0.343 ±  0.006 55 ± 4 
Pantoea agglomerans  0.328 ±  0.001 64 ± 4 
Shinella zoogloeoides  0.035 ±  0.001 36 ± 4 
 
a) maximum op tical density  values measured at 600 nm (OD600) for each trip licate experiment 
b) maximum EE2 percent removal of trip licate experiments (after 168 hours) 
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The growth curves (trip licates for each bacterium tested) of the four bacterial species with the 
EE2 removal (Acinetobacter bouvetii, Acinetobacter kookii, Pantoea agglomerans and Shinella 
zoogloeoides) and corresponding EE2 removals are illustrated in Figures 3.4a. and 3.4b.  
a) 
 
b) 
 
 
Figure 3.4 Biodegradation of 15 mg/L 17α-ethiny lestradiol (EE2) by  isolates Acinetobacter 
bouvetii, Acinetobacter kookii, Pantoea agglomerans and Shinella zoogloeoides species. (a) 
Bacterial growth; (b) removal of EE2 after 168 hours.  
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Figure 3.5. Growth pattern of the Acinetobacter bouvetii, Acinetobacter kookii, Pantoea 
agglomerans and Shinella zoogloeoides species in MSM in the p resence of glucose 10 mg/L at 
28°C for 168 h. 
 
 Positive control was again performed, with bacteria growing in p resence of glucose added 
to the media. This experiment was done in order to check for bacterial growth in p resence of 
their p referential carbon source, which was expected to be glucose. As expected, all isolates 
grew successfully  in p resence of glucose (Figure 3.5), with maximum OD values achieved with 
Pantoea agglomerans (app rox. 0.650) and lowest with Acinetobacter bouvetii (app rox. 0.050). 
On the other hand, in p resence of EE2, Acinetobacter bouvetii achieved considerably  better 
growth with OD values of 0.553 ±  0.008 (Table 3.6). This clearly  shows that Acinetobacter 
bouvetii will p referentially  use EE2 over glucose as carbon source. It is important to mention that 
for all isolates it was observed that they  reached stationary  phase after 48h, for both carbon 
sources (EE2 and glucose), meaning that they  consume EE2 at the same rate as glucose, making 
them able to switch and adap t to carbon sources other than glucose, which is a characteristic of 
gram-negative bacteria (Buffing et al., 2018). Thus, if Acinetobacter bouvetii, was grown in a 
mixture of two carbon sources (EE2 and glucose), these bacteria would first dep lete EE2 in 
MSM and then switch to glucose. As for Pantoea agglomerans, it would start first with glucose 
and EE2 would be used after all the glucose in media is spent. However, this was not confirmed 
in p ractice in this study, but it should be considered for the future. 
 It has been documented that strains from the genus Pantoea show biodegradation activity  
on various chemical pollutants especially  of soil and water, including petroleum hydrocarbons 
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and toxic metals (McGuinness and Dowling 2009). The high EE2 degradation by  the Pantoea 
agglomerans used in this study compared to the others was p rospective since this genus is known 
to be capable of degrading organic compounds with aromatic structures and phenolic moieties 
like EE2.  
 According to the results obtained by  GC-MS analy sis (typ ical chromatogram and report 
p resented in Appendix 3) the metabolic p roducts of EE2 were estrone (E1), estriol (E3) and 17b-
estradiol (E2). The experiments conducted with Shinella zoogloeoides resulted in the formation 
of a E2 metabolite that appeared after 168 h (Fig. 3.4b). This by -p roduct of EE2 degradation 
appeared to fluctuate starting after 48 hours and continuing throughout the experiment (168 
hours). Although this oscillation in metabolite peak area seems to be a strange pattern, it may  be 
a result of two different p rocesses occurring at the same time: by -product production due to EE2 
degradation and consumption by  Shinella zoogloeoides. While the ability  to transform EE2 to E1 
was observed in all 4 isolates, the ability  to degrade estrone was observed only  with one strain 
Pantoea agglomerans.  The lack of metabolite formation detected after 168 h with the most 
successful bacteria (Pantoea agglomerans) may  also be attributed to the possibility  that any  
metabolites formed were degraded as they  were p roduced, thus p reventing accumulation and 
detection. Along with the p roduction or accumulation of estrone during EE2 degradation 
p rocess, three assumptions could be done: 1) the ability  to oxidize the secondary  alcohol of EE2 
to ketone might be a common feature among these bacterial isolates. 2) estrone was a major 
metabolite during EE2 biodegradation. 3) the step  of estrone degradation may  be the rate-
limiting step  for converting estrogens, such as EE2 and estrone to no estrogenic met end 
p roducts (Bram Pauwels et al., 2008).  Previous research has shown that heterotrophic bacteria 
are capable of degrading both EE2 and its metabolites of degradation (Shi et al., 2004), which 
may  be why  this erratic pattern of metabolite peak area was observed. Another exp lanation of 
this observed fluctuating trend may  be due to the formation of several different, but structurally  
similar, metabolites over time due to the degradation of EE2 or its by -p roducts. Several studies 
reported degradation of natural and synthetic estrogens (Yu, Deeb, and Chu 2013) and 
investigated the metabolism of E2, EE2, estrone  and estriol (E3) by  activated sludge and night 
soil composting microorganisms and p roved the degradation of the natural hormones E2, E1 and 
E3 but not the synthetic steroid EE2. (Vader et al., 2000) observed and improved degradation of 
estrogens within several hours by  activated sludge with significant nitrifier capacity , underlining 
the different conditions required by  different microorganisms. Studies which monitored the 
performance of WWTPs report varied and huge differences in percentages of estrogen removals, 
ranging from 19% to 94% for E1, 76% to 92% for E2, and 83% to 87% for EE2 (Baronti et al., 
2000).   
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4. CONCLUSION 
 
 This research investigated the biodegradation of two different pharmaceutical compounds 
(fluoxetine – FLX; 17α-ethiny lestradiol – EE2) by  isolated bacteria.  
 In the p resent work it was possible to obtain bacterial isolates from a sludge of the 
oxidation ditch of the Faro Northwest WWTP (Portugal), that were able to utilize aromatic 
compounds such are FLX and EE2 as p rimary  carbon sources, under aerobic conditions. The 
selected bacterial isolates showed resistance to grow in the p resents of FLX and EE2 were 
sequenced by  16S rRNA and identified with similarity  scores above 95% as Pseudomonas 
putida, Enterobacter ludwigii, Pseudomonas nitritireducens, Alcaligenes faecalis, Pseudomonas 
aeruginosa, Pseudomonas nitroreducens, Acinetobacter bouvetii, Acinetobacter kookii, Pantoea 
agglomerans, Shinella zoogloeoideswas. The liquid assays showed that Pseudomonas 
nitroreducens disp layed the highest removal efficiency  of FLX at 20 mg/L, with 55 ± 1 % 
degradation. In case of EE2, the best result was achieved with Pantoea agglomerans, that 
degraded 64 ± 4 % of 15 mg/L EE2. These bacterial strains revealed to be successful at 
degrading these two pharmaceutical compounds, which is of a great environmental importance. 
In addition, GC/MS analy sis revealed the p resence of the following metabolites for EE2: 17b-
estradiol, estrone and estriol are easily  biodegradable than the parent compound. 
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5. RECOMENDATIONS 
 Based on the obtained results and conclusions of this thesis, the following 
recommendations for future study  are suggested in order to onward increase the current 
knowledge on this subject: 
I. In this study  Pantoea agglomerans was identified as a bacterial isolate that was 
successful to degrade EE2; Pseudomonas aeruginosa and Pseudomonas nitroreducens 
degraded FLX individually . Other pharmaceutical compounds should be investigated in 
order to exp lore the app licability  of these bacterial isolates for the biological removal of a 
variety  of different pharmaceutical.  
II. The biodegradation of more pharmaceutical compounds should also be studied with the 
bacterial mixtures (already  obtained bacteria isolates) in order to obtained better removal 
for FLX and EE2. Bioaugmentation can be done by  adding lab p roduced biomass in order 
to improve the wastewater treatment p rocesses. 
 
III. This study  tested higher concentrations of FLX and EE2 than those that have been 
measured in wastewaters and surface waters for each of pharmaceutical compounds, thus  
increasing experimental p recision and analy tical accuracy . However, experiments using 
lower concentrations of pharmaceutical compounds in the range of ng/L to µg/L should 
be carried out in order to see how fast they  will achieve maximum removal at the low 
pharmaceutical concentration levels. 
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7. APPENDIXES 
 
Appendix 1. 
 
Table 1. Contig0 sequences with corresponded bacterial isolates.  
Name Isolate BioEdit Contig0 Sequences 
 
 
 
Pseudomonas 
putida 
 
 
 
1 
 
 
ATAGAGTTGGAACTCGAGCCAGAAAGACAAGAGCTT
GCTCTTAGATTCAGCGGCGGACGGGTGAGTAATGCC
TAGGAATCTGCCTGGTAGTGGGGGACAACGTTTCGA
AAGGAACGCTAATACCGCATACGTCCTACGGGAGAA
AGCAGGGGACCTTCGGGCCTTGCGCTATCAGATGAG
CCTAGGTCGGATTAGCTAGTTGGTGAGGTAATGGCT
CACCAAGGCGACGATCCGTAACTGGTCTGAGAGGAT
GATCAGTCACACTGGAACTGAGACACGGTCCAGACT
CCTACGGGAGGCAGCAGTGGGGAATATTGGACAATG
GGCGAAAGCCTGATCCAGCCATGCCGCGTGTGTGAA
GAAGGTCTTCGGATTGTAAAGCACTTTAAGTTGGGA
GGAAGGGCATTAACCTAATACGTTAGTGTTTTGACG
TTACCGACAGAATAAGCACCGGCTAACTCTGTGCCA
GCAGCCGCGGTAATACAGAGGGTGCAAGCGTTAATC
GGAATTACTGGGCGTAAAGCGCGCGTAGGTGGTTTG
TTAAGTTGGATGTGAAAGCCCCGGGCTCAACCTGGG
AACTGCATCCAAAACTGGCAAGCTAGAGTACGGTAG
AGGGTGGTGGAATTTCCTGTGTAGCGGTGAAATGCG
TAAATATAGGAAAGGAACACCAGTGGCGAAGGCGA
CCACCTGGACTGATACTGACACTGAGGTGCGAAAGC
GTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCC
ACGCCGTAAACGATGTCAACTAGCCGTTGGAATCCT
TGAGATTTTAGTGGCGCAGCTAACGCATTAAGTTGA
CCGCCTGGGGAGTACGGCCGCAAGGGTTAAAACTCA
AATGAATTGACGGGGGCCCGCACAAGCGGTGGAAG
CATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTA
CCAGGCCTTGACATGCAGAGAACTTTCCAGAGATGG
ATTGGTGCCTTCGGGAACTCTGACACAGGTGCTGCA
TGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTA
AGTCCCGTAACGAGCGCAACCCTTGTCCTTAGTTACC
AGCACGTAATGGTGGGCACTCTAAGGAGACTGCCGG
TGACAAACCGGAGGAAGGTGGGGATGACGTCAAGT
CATCATGGCCCTTACGGCCTGGGCTACACACGTGCT
ACAATGGTCGGTACAGAGGGTTGCCAAGCCGCGAGG
TGGAGCTAATCTCACAAAACCGATCGTAGTCCGGAT
CGCAGTCTGCAACTCGACTGCGTGAAGTCGGAATCG
CTAGTAATCGCGAATCAGAATGTCGCGGTGAATACG
TTCCCGGGCCTTGTACACACCGCCCGTCACACCATGG
GAGTGGGTTGCTCCAGAAGTAGCTAGTTTAACCTGT
CGGGAGGAACGGTTACCCT 
 
43 
 
 
 
Enterobacter 
ludwigii 
 
 
 
 
2 
 
 
TGCAAGTCGGGCGGTAACACGGGGGAGCTTGCTCCT
GGGTGACGAGCGGCGGACGGGTGAGTAATGTCTGGG
AAACTGCCTGATGGAGGGGGATAACTACTGGAAACG
GTAGCTAATACCGCATAACGTCGCAAGACCAAAGAG
GGGGACCTTCGGGCCTCTTGCCATCAGATGTGCCCA
GATGGGATTAGCTAGTAGGTGGGGTAACGGCTCACC
TAGGCGACGATCCCTAGCTGGTCTGAGAGGATGACC
AGCCACACTGGAACTGAGACACGGTCCAGACTCCTA
CGGGAGGCAGCAGTGGGGAATATTGCACAATGGGC
GCAAGCCTGATGCAGCCATGCCGCGTGTATGAAGAA
GGCCTTCGGGTTGTAAAGTACTTTCAGCGGGGAGGA
AGGTGTTGTGGTTAATAACCACAGCAATTGACGTTA
CCCGCAGAAGAAGCACCGGCTAACTCCGTGCCCAGC
AGCCGCGGTAATACGGAGGGTGCAAGCGTTAATCGG
AATTACTGGGCGTAAAGCGCACGCAGGCGGTCTGTC
AAGTCGGATGTGAAATCCCCGGGCTCAACCTGGGAA
CTGCATTCGAAACTGGCAGGCTAGAGTCTTGTAGAG
GGGGGTAGAATTCCAGGTGTAGCGGTGAAATGCGTA
GAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCC
CTGGACAAAGACTGACGCTCAGGTGCGAAAGCGTGG
GGAGCAAACAGGATTAGATACCCTGGTAGTCCACGC
CGTAAACGATGTCGACTTGGAGGTTGTGCCCTTGAG
GCGTGGCTTCCGGAGCTAACGCGTTAAGTCGACCGC
CTGGGGAGTACGGCCGCAAGGTTAAAACTCAAATGA
ATTGACGGGGGGCCCGCACAAGCGGTGGAGCATGTG
GTTTAATTCGATGCAACGCGAAGAACCTTACCTACTC
TTGACATCCAGAGAACTTAGCAGAGATGCTTTGGTG
CCTTCGGGAACTCTGAGACAGGTGCTGCATGGCTGT
CGTCAGCTCGTGTTGTGAAATGTTGGGTTAAGTCCCG
CAACGAGCGCAACCCTTATCCTTTGTTGCCAGCGGTC
CGGCCGGGAACTCAAAGGAGACTGCCAGTGATAAAC
TGGAGGAAGGTGGGGATGACGTCAAGTCATCATGGC
CCTTACGAGTAGGGCTACACACGTGCTACAATGGCG
CATACAAAGAGAAGCGACCTCGCGAGAGCAAGCGG
ACCTCATAAAGTGCGTCGTAGTCCGGATTGGAGTCT
GCAACTCGACTCCATGAAGTCGGAATCGCTAGTAAT
CGTAGATCAGAATGCTACGGTGAATACGTTCCCGGG
CCTTGTACACACCGCCCGTCACACCATGGGAGTGGG
TTGCTAAAAGAAGTAGGTAGCTTAACCTTCGGGAGG
GCG 
 
 
 
 
Pseudomonas 
nitritireducens 
 
 
 
 
3 
 
 
CGAGCGGATGATCGGTGAAGCTTGCTCCCAGATTCA
GCGGCGGACGGGTGAGTAATGCCTAGGAATCTGCCT
GGTAGTGGGGGACAACGTTTCGAAAGGAACGCTAAT
ACCGCATACGTCCTACGGGAGAAAGCAGGGGACCTT
CGGGCCTTGCGCTATCAGATGAGCCTAGGTCGGATT
AGCTAGTTGGTGGGGTAAAGGCCTACCAAGGCGACG
ATCCGTAACTGGTCTGAGAGGATGATCAGTCACACT
44 
 
GGAACTGAGACACGGTCCAGACTCCTACGGGAGGCA
GCAGTGGGGAATATTGGACAATGGGCGAAAGCCTGA
TCCAGCCATGCCGCGTGTGTGAAGAAGGTCTTCGGA
TTGTAAAGCACTTTAAGTTGGGAGGAAGGGCAGTAA
GTTAATACCTTGCTGTTTTGACGTTACCAACAGAATA
AGCACCGGCTAACTTCGTGCCAGCAGCCGCGGTAAT
ACGAAGGGTGCAAGCGTTAATCGGAATTACTGGGCG
TAAAGCGCGCGTAGGTGGTTTGGTAAGATGGATGTG
AAATCCCCGGGCTCAACCTGGGAACTGCATCCATAA
CTGCCTGACTAGAGTACGGTAGAGGGTGGTGGAATT
TCCTGTGTAGCGGTGAAATGCGTAGATATAGGAAGG
AACACCAGTGGCGAAGGCGACCACCTGGACTGATAC
TGACACTGAGGTGCGAAAGCGTGGGGAGCAAACAG
GATTAGATACCCTGGTAGTCCACGCCGTAAACGATG
TCGACTAGCCGTTGGAATCCTTGAGATCTTAGTGGCG
CAGCTAACGCGATAAAGTCGACCGCCTGGGGAGTAC
GGCCGCAAGGTTAAAACTCAAATGAATTGACGGGGG
CCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAA
GCAACGCGAAGAACCTTACCTGGCCTTGACATGTCC
GGAATCTTGCAGAGATGCGAGAGTGCCTTCGGGAAT
CGGAACACAGGTGCTGCATGGCTGTCGTCAGCTCGT
GTCGTGAGATGTTGGGTTAAGTCCCGTAACGAGCGC
AACCCTTGTCCTTAGTTACCAGCACGTTAAGGTGGGC
ACTCTAAGGAGACTGCCGGTGACAAACCGGAGGAA
GGTGGGGATGACGTCAAGTCATCATGGCCCTTACGG
CCAGGGCTACACACGTGCTACAATGGTCGGTACAGA
GGGTTGCCAAGCCGCGAGGTGGAGCTAATCCCATAA
AACCGATCGTAGTCCGGATCGCAGTCTGCAACTCGA
CTGCGTGAAGTCGGAATCGCTAGTAATCGTGAATCA
GAATGTCACGGTGAATACGTTCCCGGGCCTTGTACA
CACCGCCCGTCACACCATGGGAGTGGGTTGCTCACA
GAAGTATGCCTAGTCTAACCGCAAGGGGGACGGTTA
CCAG 
 
 
 
 
Alcaligenes 
faecalis 
 
 
 
 
4 
 
 
GAACGGCAGCTGCGTAGAGAGCTTAGCTATCTTGGC
GGCGAGTGGCGGACGGGTGAGTAATATATCGGAACG
TGCCCAGTAGCGGGGGATAACTACTCGAAAGAGTGG
CTAATACCGCATACGCCCTACGGGGGAAAGGGGGGG
ATCGCAAGACCTCTCACTATTGGAGCGGCCGATATC
GGATTAGCTAGTTGGTGGGGTAAAGGCTCACCAAGG
CAACGATCCGTAGCTGGTTTGAGAGGACGACCAGCC
ACACTGGGACTGAGACACGGCCCAGACTCCTACGGG
AGGCAGCAGTGGGGAATTTTGGACAATGGGGGAAA
CCCTGATCCAGCCATCCCGCGTGTATGATGAAGGCC
TTCGGGTTGTAAAGTACTTTTGGCAGAGAAGAAAAG
GTACCTCCTAATACGAGGTACTGCTGACGGTATCTGC
AGAATAAGCACCGGCTAACTACGTGCCAGCAGCCGC
GGTAATACGTAGGGTGCAAGCGTTAATCGGAATTAC
TGGGCGTAAAGCGTGTGTAGGCGGTTCGGAAAGAAA
GATGTGAAATCCCAGGGCTCAACCTTGGAACTGCAT
45 
 
TTTTAACTGCCGAGCTAGAGTATGTCAGAGGGGGGG
TAGAATTCCACGTGTAGCAGTGAAATGCGAAATATG
TGGAGGAATACCGATGGCGAAGGCGCCCCCCTGGGA
TAATACTGACGCTCAGACACAAAGCGTGGGGAGCAA
ACAGGATTAATACCCTGGTAGTCCACGCCCTA 
 
 
 
 
Pseudomonas 
aeruginosa 
 
 
 
 
5 
 
 
TTTGATCTCGGCTCAGAAGTCGGTGAAGCTTGTTCCC
GGATTCAGCGGCGGACGGGTGAGTAATGCCTAGGAA
TCTGCCTGGTAGTGGGGGATAACGTCCGGAAACGGG
CGCTAATACCGCATACGTCCTGAGGGAGAAAGTGGG
GGATCTTCGGACCTCACGCTATCAGATGAGCCTAGG
TCGGATTAGCTAGTTGGTGGGGTAAAGGCCTACCAA
GGCGACGATCCGTAACTGGTCTGAGAGGATGATCAG
TCACACTGGAACTGAGACACGGTCCAGACTCCTACG
GGAGGCAGCAGTGGGGAATATTGGACAATGGGCGA
AAGCCTGATCCAGCCATGCCGCGTGTGTGAAGAAGG
TCTTCGGATTGTAAAGCACTTTAAGTTGGGAGGAAG
GGCAGTAAGTTAATACCTTGCTGTTTTGACGTTACCA
ACAGAATAAGCACCCGGCTAACTTCGTGCCAGCAGC
CGCGGTAATACGAAGGGTGCAAGCGTTAATCGGAAT
TACTGGGCGTAAAGCGCGCGTAGGTGGTTCAGCAAG
TTGGATGTGAAATCCCCGGGCTCAACCTGGGAACTG
CATCCAAAACTACTGAGCTAGAGTACGGTAGAGGGT
GGTGGAATTTCCTGTGTAGCGGTGAAATGCGTAGAT
ATAGGAAGGAACACCAGTGGCGAAGGCGACCACCT
GGACTGATACTGACACTGAGGTGCGAAAGCGTGGGG
AGCAAACAGGATTAGATACCCTGGTAGTCCACGCCG
TAAACGATGTCGACTAGCCGTTGGGATCCTTGAGAT
CTTAGTGGCGCAGCTAACGCGATAAGTCGACCGCCT
GGGGAGTACGGCCGCAAGGTTAAAACTCAAATGAAT
TGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGGT
TTAATTCGAAGCAACGCGAAGAACCTTACCTGGCCT
TGACATGCTGAGAACTTTCCAGAGATGGATTGGTGC
CTTCGGGAACTCAGACACAGGTGCTGCATGGCTGT C
GTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGT
AACGAGCGCAACCCTTGTCCTTAGTTACCAGCACCTC
GGGTGGGCACTCTAAGGAGACTGCCGGTGACAAACC
GGAGGAAGGTGGGGATGACGTCAAGTCATCATGGCC
CTTACGGCCAGGGCTACACACGTGCTACAATGGTCG
GTACAAAGGGTTGCCAAGCCGCGAGGTGGAGCTAAT
CCCATAAAACCGATCGTAGTCCGGATCGCAGTCTGC
AACTCGACTGCGTGAAGTCGGAATCGCTAGTAATCG
TGAATCAGAATGTCACGGTGAATACGTTCCCGGGCC
TTGTACACACCGCCCGTCACACCATGGGAGTGGGTT
GCTACAGAAGTAGCCTAGTCTAACAACAAGGGGCAA
GGTAAC 
 
 
 
Pseudomonas 
 
 
7 
 
 
GCATAGAGTTGGATCTCGAGCGGATGATGGGAGCTT
46 
 
nitroreducens 
 
GCTCCCGGATTCAGCGGCGGACGGGTGAGTAATGCC
TAGGAATCTGCCTGGTAGTGGGGGACAACGTTTCGA
AAGGAACGCTAATACCGCATACGTCCTACGGGAGAA
AGCAGGGGACCTTCGGGCCTTGCGCTATCAGATGAG
CCTAGGTCGGATTAGCTAGTTGGTGGGGTAAAGGCC
TACCAAGGCGACGATCCGTAACTGGTCTGAGAGGAT
GATCAGTCACACTGGAACTGAGACACGGTCCAGACT
CCTACGGGAGGCAGCAGTGGGGAATATTGGACAATG
GGCGAAAGCCTGATCCAGCCATGCCGCGTGTGTGAA
GAAGGTCTTCGGATTGTAAAGCACTTTAAGTTGGGA
GGAAGGGCAGTAAGTTAATACCTTGCTGTTTTGACG
TTACCAACAGAATAAGCACCGGCTAACTTCGTGCCA
GCAGCCGCGGTAATACGAAGGGTGCAAGCGTTAATC
GGAATTACTGGGCGTAAAGCGCGCGTAGGTGGTTTG
GTAAGATGGATGTGAAATCCCCGGGCTCAACCTGGG
AACTGCATCCATAACTGCCTGACTAGAGTACGGTAG
AGGGTGGTGGAATTTCCTGTGTAGCGGTGAAATGCG
TAGATATAGGAAGGAACACCAGTGGCGAAGGTCGA
CCACCTGGACTGATACTGACACTGAGGTGCGAAAGC
GTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCC
ACGCCGTAAACGATGTCGACTAGCCGTTGGGATCCT
TGAGATCTTAGTGGCGCAGCTAACGCGATAAAGTCG
ACCGCCTGGGGAGTACGGCCGCAAGGTTAAAACTCA
AATGAATTGACGGGGGCCCGCACAAGCGGTGGAGC
ATGTGGTTTAATTCGAAGCAACGCGAAAGAACCTTA
CCTTGGCCTTGACATGTCCGGAACTTTGCAGAGATGT
GAGGGTGCCTTTGGGAATCGGAACACAGGTGCTGCA
TGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTA
AGTCCCGTAACGAGCGCAACCCTTGTCCTTAGTTACC
AGCACGTTATGGTGGGCACTCTAAGGAGACTGCTGG
TGACAAACCGGAGGAAGGTGGGGATCGCGTCAAGTC
ATCATGGCCCTTACGTCCAGGGCTACACACGTGCTA
CAATGGTCGGTACAGAGGGTTGCCAAGCCGCGAGGT
GGAGCTAATCCCATAAAACCGATCGTAGTCCGGATC
GCAGTCTGCAATTTGACTGCGTGAAGTCGGAATCGT
TAGTAATCGTGAATCAGAATGTCACGGTGATTACTTT
TCTGTTCTTTGTACACACTGCCCGTCACACCATGGGA
GTGGGTTGCTCCAGATGTAGCTAGTCTAACCACAAG
GGGCAAGGTTACCCAAT 
 
 
 
 
Acinetobacter 
bouvetii 
 
 
 
 
8 
 
 
 
TGCAAGTCGAGCGGAGTTGTGGTGCTTGCACCATAACTT
AGCGGCGGACGGGTGAGTAATGCTTAGGAATCTGCCTA
TTAGTGGGGGACAACGTTTCGAAAGGAACGCTAATACC
GCATACGCCCTACGGGGGAAAGCAGGGGATCTTCGGAC
CTTGCGCTAATAGATGAGCCTAAGTCAGATTAGCTAGTT
GGTGGGGTAAAGGCCTACCAAGGCGACGATCTGTAGCG
GGTCTGAGAGGATGATCCGCCACACTGGGACTGAGACA
CGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATAT
TGGACAATGGGGGGAACCCTGATCCAGCCATGCCGCGT
47 
 
GTGTGAAGAAGCCCTTTTGGTTGTAAAGCACTTTAAGCG
AGGAGGAGGCTCTTCTAGTTAATACCTAGGATGAGTGGA
CGTTACTCGCAGAATAAGCACCGGCTAACTCTGTGCCAG
CAGCCGCGGTAATACAGAGGGTGCGAGCGTTAATCGGA
TTTACTGGGCGTAAAGCGTACGTAGGCGGCTTTTTAAGT
CGGATGTGAAATCCCTGAGCTTAACTTAGGAATTGCATT
CGATACTGGGAAGCTAGAGTATGGGAGAGGATGGTAGA
ATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAG
GAATACCGATGGCGAAGGCAGCCATCTGGCCTAATACT
GACGCTGAGGTACGAAAGCATGGGGAGCAAACAGGATT
AGATACCCTGGTAGTCCATGCCGTAAACGATGTCTACTA
GCCGTTGGGGCCTTTGAGGCTTTAGTGGCGCAGCTAAC
GCGATAAGTAGACCGCCTGGGGAGTACGGTCGCAAGAC
TAAAACTCAAATGAATTGACGGGGGCCCGCACAAGCGG
TGGAGCATGTGGTTTAATTCGATGCAACGCGAAGAACCT
TACCTGGTCTTGACATAGTAAGAACTTTCCAGAGATGGA
TTGGTGCCTTCGGGAACTTACATACAGGTGCTGCATGGC
TGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCC
GCAACGAGCGCAACCCTTTTCCTTATTTGCCAGCGGGTT
AAGCCGGGAACTTTAAGGATACTGCCAGTGACAAACTG
GAGGAAGGCGGGGACGACGTCAAGTCATCATGGCCCTT
ACGACCAGGGCTACACACGTGCTACAATGGTCGGTACA
AAGGGTTGCTACCTAGCGATAGGATGCTAATCTCAAAAA
GCCGATCGTAGTCCGGATTGGAGTCTGCAACTCGACTC
CATGAAGTCGGAATCGCTAGTAATCGCGGATCAGAATGC
CGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCC
GTCACACCATGGGAATTTGTTGCACCAGAAGTAGGTAGT
CTAACCGCAAGGAGGACGCTT 
 
 
 
 
Acinetobacter 
kookii 
 
 
 
 
11 
 
 
TTAGAGTTTGATCTCGGCTCGAAGTCGTTGCTTCGGT
AACAGACCTAGCGGCGGACGGGTGAATAATGCTTAT
GAATCTGCCTATTAGTGGGGGACAACATCTCGAAAG
GGATGCTAATACCGCATACGTCCTACGGGAGAAAGC
AGGGGACCTTCGGGCCTTGCGCTAATATATGAGCCT
AAGTCGGATTAACTAGTTGGTGGGGTAAAGGCCTAC
CAAGGCGACGATCTGTAGCGGGTCTGAAAGGATGAT
CCGCCACCCTGGGACTGACACACGGCCCAAACTCCT
ACGGGAGGCAGCAGTGGGGAATATTGGACAATGGG
GGGAACCCTGATCCACCCATGCCGCGTGTGTGAATA
AGGCCTTTTGGTTGTAAAGCACTTTAAACGAGGAGG
AGGCTACTGGTATTAATACTACCGGATAGTGGACGT
TACTCGCAGAATAATCACCGGCTAACTCTGTGCCAA
CAGCCGCGGTAATACACAGGGTGCGAGCGTTAATCG
GATTTACTGGGCGTAAAGCGTGCGTATGCGGCTTTTT
AAGTCGGATGTGAAATCCCTGAGCTTAACTTAGGAA
TTGCATTCGATACTGGGAGGCTAGAGTATGGGAGAG
GATGGTAGAATTCCAGGTGTAGCGGTGAAATGCGTA
CAGATCTGGAGGAATACCGATGGCGAAGGCAGCCAT
CTGGCCTAATACTGACGCTGAGGTACGAAAGCATGG
GGAGCAAACAGGATTAGATACCCTGGTAGTCCATGC
48 
 
CGTAAACGATGTCTACTAGCCGTTGGGGCCTTTGAG
ACTTTAGTGGCGCAGATAACGCGATAAGTACACCGC
CTGGGGAGTACGGTCGCAAGACTAAAACTCAAATGA
ATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGG
TTTAATTCGATGCAACGCGAAGAACCTTACCTGGTCT
TTACATACAGAGAACTTTCCAGAGATGGATTGGTGC
CTTTGGGAACTCTGATACAGGTGCTTCATGGCTGTCG
TCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCA
ACGAGCGCAACCCTTTTCCTTACTTGCCATCGGGTCA
TGCCGGGAATTTTAAGGATACTGCCAGTGACAAACT
GGAGGAAGGCGGGGACGACGTCAAGTCACAATGGC
CCTTACGACCATGGCTACACACGTGCTACAATGGTC
GGTACAAAGGGTTGCTACCTAGCGATAGGATGTTAA
TTTCAAAAATCCGATCGTAGTCCGGATTGGAGTCTGC
AACTCGATTCCATGAAGTTGGAATCGTTAGTAATCG
CGGATCAGAATGCCGCGGTGAATACGTTCCCGGGCT
TTGTACACACCGCCCGTCACACCATGGGAGTTTGTTG
CTCCAGAAGTAGGTTGCTAACCGCAAGTAACAAGGT
AACCCT 
 
 
 
 
Pantoea 
agglomerans 
 
 
 
 
12 
 
 
ACTTGCAAGTCGGGCGGTAACACGGGTGCTTGTGCT
CCCGGTTGACGACCGGCGGATGGGTGATGATTGTCA
GGGAGCCTGCTTGAGGGAGGGGGATATCTACTGGGA
ACGGTAACTAATACCGCATACCATCGCAGAACCCAA
GAGAGCTACCTTCCTTCCTCTTGCCATCGAATGTGCC
CCGATGTAATTAGCTGGTGGGTGGGGTAACGGCTCA
CCTAAGCAACTATCCCTAGCTGGTCTGAAAGGATGA
CCACCCTCACTGTAACTGACACCCCGTCCTCACTCCT
ACGGGAGGCATGGGTGGGAAATATTGCAGAATGGG
CGCCTGCCTGATGCATGCATGCCGCGTGTATGAAGA
ATGCCTTCTGTTTGTAAATTACTTTCACGAGGAAGGA
ACTTGTTGTGATTAATAATCACGACTAGTGGACGTTA
CTACCCAGAATAAGAACCGGCTAACTCCGTGCCAGC
CAGCCGCGGTAAAATACAGAGGGTGCAAGCGTTAAT
CGGATTTTTACTGGGCGTAAAGCGCACACGCAGGCG
GTTTTTCAAGTCAGATGTGAAATCCCCGAGCTCAACC
TGAGAACTGCATTCGATACGTGGCAAGCTAGAATAT
TGGTAGAAGGATGGTAAAATTCCAGTGTGTAGCGGA
GAAATGCATAGAGATCTGGAAGAATACCGATGGCGA
ACGCCCCCCTCGTGGACAAACACTGACGCTCAGTGT
GCGAACAGCGTGGGAGAACAAACAGGATAATAGAT
ACCCTGGGTAGTCCACGCCGTAAACGATGTCTACTA
TTGCGACGTTGGGCCCTTGAGGCGTGGCTGTCCGCA
GCTAAACGCGATAAGTACAACCGCCTGGGGGGAGTA
CGGTCGTCAGAGGTAAAACACTCAAATGAATTTGAC
GGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAA
TTCGATGCAACGCGAAGAACCTTACCTAGTCTTGAC
ATCCAGAGAACTTTCCAGAGATGGATTGGTGCCTTC
GGGAACTCTGAGACAGGTGCTGCATGGCTGTCGTCA
GCTCGTGTTGTGAAATGTTGGGTTAAGTCCCGCAAC
49 
 
GAGCGCAACCCTTTTCCTTTGTTGCCAGCGGTTAGGC
CGGGAACTCAAAGGAGACTGCCAGTGATAAACTGGA
GGAAGGTGGGGATGACGTCAAGTCATCATGGCCCTT
ACGAGTAGGGCTACACACGTGCTACAATGGTGCATA
CAAAGAGAAGCGACCTCGCGAGAGCAAGCGGACCT
CATAAAGTGCGTCGTAGTCCGGATTGGAGTCTGCAA
CTCGACTCCATGAAGTCGGAATCGTTAGTATTCGTAG
ATCAGAAGCCTACGGTGAATACGTTCCCGGCCCTGG
TCCCCCCCCCCCTCCCCCCCATGGGATTGGGTTCCAC
AGAAATTAGTTACCTAAACCCTAGGGAGGGCGTT 
 
 
 
Shinella 
zoogloeoides 
 
 
 
13 
 
TAGAGTTTGATCCTGGCTCAGAAGTCGTAACAAGGT
AACCAGTTAGAGTTTGATCCTGGCTCCGAAGCCGTTC
CACGGAAAACATCAGGAAAACTTGTGCGAATACCGT
ATACGCCCTTCGGGGGAAAAATTTATCGGAGTTGGA
TGAGCCCCCGTTGGATTAGCTAGTTGGTGGGGTAAA
GGCCTACCAAGGCGACGATCCATAACTGGTCTGAGA
GGATGATCACCCACATTGGGACTGAGACACGGCCCA
AACTCCTACGGGAGGCAGCAGTGGGGAATATTGGAC
AATGGGCGCAAGCCTGATCCACCCATGCCGCGTGAG
TGATGAAGGCCCTAGGGTTGTAAAGCTCTTTCACCG
GTGAAGATAATGACGGTAACCGGAGAAAAAGCCCC
GGCTAACTTCGTGCCAGCAGCCGCGGTAATACGAAA
GGGGCTAGCGTTGTTCGGAATCACTGGGCGTAAAGC
GCACGTAGGCGGGTATTTAAGTCAGGGGTGAAATCC
CAGAGCTCAACTCTGGAACTGCCTTTGATAATGGGT
ACCTACAGTATGGAAGAGGTAAGTGGAATTCCTGAG
TGTAGAGGTGAAATTCGTAGATATTCGGAGGAACAC
CACTGGCGAAGGCGGGCTAACTGGTCCCATTACTGA
CGCTGAGGTGCGAAAACGTGGGGAGCAAACAGGAT
TAGATACCCTGGTAGTCCACCCCGTAAACAATGAAT
GTGACCCGCCGGCAGGCAGGCATGGTCGGAGGCGCA
GCTAACGCATTAAACATTCCGCCTGGGGAGTACGGT
CGCAAGATTAAAACTCAAAGGAATTGACGGGGGCCC
GCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCA
ACGCGCAGAACCTTACCAGCCCTTGACATGTCGGTC
GCGGATTACAGAGATGTTTTCCTTCAGTTAGGCTGGA
CCGAACACAGGTGCTGCATGGCTGTCGTCAGCTCGT
GTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGC
AACCCTCGCCCTTAGTTGCCAGCATTCAGTTGGGCAC
TCTAAGGGGACTGCCGGTGATAAGCCGAGAGGAAG
GTGGGGATGACGTCAAGTCCTCATGGCCCTTACGGG
CTGGGCTACACACGTGCTACAATGGTGGTGACAGTG
GGCAGCGAGACAGCGATGTCGAGCTAATCTCCAAAA
GCCATCTCAGTTCGGATTGCACTCTGCAACTCGAGTG
CATGAAGTTGGAATCGCTAGTAATCGCGGATCAGCA
TGCCGCGGTGAATACGTTCCCTGGCCTTGTACACACC
GCCCGTCACACCATCAGAGTAGCCTTTTAGAGTTTGA
TCCTGGCTCAGAAGTCGTAACAAGGTAACCTG 
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Appendix 2. 
 
Figure 1. Rep resentative HPLC chromatogram of FLX at 226 nm. 
 
Figure 2. FLX calibration curve for HPLC analy sis. 
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Appendix 3. 
 
Figure 3. EE2 calibration curve for GC/MS analy sis. 
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Figure 4. GC-MS report of EE2 analy sis 
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